Optivia in the News
FREE ROAD MAP TO FDA WHITE-PAPER
The ITC Transporter White Paper provides detailed guidance for transporter mediated DDI studies for the seven transporters recommended in the March 17, 2010 FDA Advisory Committee vote. Get the White Paper and a Road Map Summary to help navigate it.
QUESTIONS?
Speak with one of our transporter specialists about your needs to understand how we can help you and the results you can expect.
CONTACT US:
888-OPTIVIA (888-678-4842)
Optivia in the News
April 5, 2011
"Optivia Wins $1.85M Phase II Grant to Develop Drug-Drug Interaction Assays"
Transporter assay services firm Optivia Biotechnologies won a $1.85 million Phase II SBIR grant from the National Institute of General Medical Sciences to fund development of a broad set of assays and databases for use in identifying clinically significant drug-drug interactions that involve membrane transporters...... Click to read the entire article in Genetic Engineering and Biotechnology News.
February 1, 2011
"Optivia Signs Agreement With U.S. FDA To Assess Role Of Dietary Supplements In Drug-Induced Liver Injury"
Research Will Evaluate Effect of Dietary Supplements on Key Drug Transporters
Reported in USA Today, BioSpace, FierceBiotech.com, Drug Store News and Pharmaceutical Business Review.
January 1, 2011
"Optivia builds on UCSF work to predict liver toxicity of drugs in development"
MENLO PARK, Calif.—In a collaboration that could represent an important step forward toward ensuring drug safety and increasing drug efficacy by building the first transporter-based assay system capable of predicting ADME (absorption, distribution, metabolism and excretion) and reducing drug-induced liver toxicity, Optivia Biotechnology Inc. provider of in-vitro transporter assay services, will collaborate with the University of California, San Francisco (UCSF) to develop an innovative system for characterizing the role transporter proteins play in the disposition of drugs by the liver.
The partners have received a $430,000 Phase I grant to leverage the expertise of Dr. Leslie Z. Benet, an internationally recognized drug development expert and professor and chairman emeritus in UCSF’s department of bioengineering and therapeutic sciences, along with Optivia’s novel transporter technology platform to study the effects of transporters on drug disposition and the interplay of transporters and metabolizing enzymes in the liver..... Click to read the entire article in Drug Discovery News, Volume 7, Number 1.
July 1, 2010
Optivia is profiled in the July/August 2010 issue of START-UP Magazine
START-UP Magazine is published by Elsevier and covers the life science industry including pharmaceutical and biotechnology companies. "Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas"